

Contents

1 Occurrence and Importance of Ether Lipids in Brain	1
1.1 Introduction.....	1
1.2 Classification of Ether Lipids Found in Brain.....	2
1.3 Physicochemical Properties of Ether Lipids.....	3
1.4 Fecapentaenes: The Novel Plasmalogens.....	4
1.5 Other Ether Lipids Found in Mammalian Tissues.....	6
1.6 Lipid Metabolism in Ether Lipid-Deficient Mice.....	10
1.7 Conclusion.....	12
References.....	13
2 Biosynthesis of Plasmalogens in Brain	17
2.1 General Considerations and Distribution of Plasmalogens in Brain...	17
2.2 Biosynthesis of Plasmalogens.....	18
2.2.1 Dihydroxyacetone Phosphate Acyltransferase.....	20
2.2.2 Alkyl Dihydroxyacetone Phosphate Synthase.....	23
2.2.3 Acyl/alkyl Dihydroxyacetone Phosphate Reductase.....	25
2.2.4 Alkylglycerophosphate Acyltransferase.....	26
2.2.5 Alkylacyl Glycerophosphate Phosphohydrolase.....	26
2.2.6 CDP-Ethanolamine: Diacylglycerol Ethanolaminephosphotransferase.....	27
2.3 Plasmalogen Synthesizing Enzymes During Brain Development.....	28
2.4 Topology and Distribution of Plasmalogens and Enzymes Synthesizing Plasmalogens.....	29
2.5 Plasmalogens in Lipid Rafts.....	30
2.6 Plasmalogens in the Nucleus.....	30
2.7 Factors Affecting Plasmalogen Biosynthesis in Brain.....	31
2.8 Conclusion.....	32
References.....	33

3	Catabolism of Plasmalogens in Brain	39
3.1	Introduction.....	39
3.2	Plasmalogen-Selective Phospholipase A ₂ (PlsEtn-PLA ₂).....	39
3.3	Receptor-Mediated Degradation of Plasmalogens	44
3.4	Regulation of PlsEtn-PLA ₂	48
3.5	Turnover of Plasmalogen in Brain.....	49
3.6	Remodeling of Plasmalogens (Reacylation/ Deacylation Reactions).....	50
3.7	Degradation of Plasmalogens by Phospholipase C	51
3.8	Nonenzymic Oxidation of Plasmalogens in Brain.....	51
3.9	Plasmalogen-Derived Lipid Mediators and Their Importance in Brain	54
3.10	Lysoplasmalogens in Brain.....	58
3.11	Conclusion	59
	References.....	59
4	Assay and Purification of Plasmalogen-Selective Phospholipase A₂ and Lysoplasmalogenase Activities	67
4.1	Introduction	67
4.2	Determination of PlsEtn and PlsCho-PLA ₂ by Radiochemical Procedures	68
4.2.1	Preparation of Radiolabeled [³ H] Plasmenylcholine (Choline Plasmalogen)	68
4.2.2	Labeling of Lysoplasmenylcholine at the <i>Sn</i> -2 Position.....	70
4.2.3	Determination of PlsCho-PLA ₂ Activity.....	70
4.2.4	Determination of PlsEtn-PLA ₂ by Fluorometric Assay	71
4.2.5	Purification of Ethanolamine Plasmalogen.....	72
4.2.6	Labeling of Ethanolamine Plasmalogen with Pyrenesulfonyl Chloride.....	72
4.2.7	Determination of PlsEtn-PLA ₂ Activity with Pyrene-Labeled Plasmalogen	73
4.2.8	Continuous Spectrophotometric Determination of PlsEtn-PLA ₂	74
4.2.9	Determination of Lysoplasmalogenase	74
4.2.9.1	Continuous Spectrophotometric Procedure for Lysoplasmalogenase	75
4.2.9.2	Continuous Spectrofluorometric Procedure for Lysoplasmalogenase	76
4.3	Activities of Plasmalogen-Selective PLA ₂ in Brains of Various Animal Species and Cultured Cells of Neuronal and Glial Origin.....	78
4.4	Determination of Lysoplasmalogenase Activity in Rat Liver and Brain Microsomes	78
4.5	Purification of Plasmalogen-Selective PLA ₂ from Brain.....	80
4.6	Purification of Lysoplasmalogenase from Liver.....	80

4.7 Conclusion.....	81
References.....	81
5 Roles of Plasmalogens in Brain.....	85
5.1 Introduction.....	85
5.2 Roles of Plasmalogens in Brain.....	85
5.2.1 Plasmalogens as Neural Membrane Components.....	85
5.2.2 Plasmalogens as a Storage Depot for Second Messengers and Lipid Mediators.....	86
5.2.3 Plasmalogens in Regulation of Enzymic Activities.....	91
5.2.4 Plasmalogens in Membrane Fusion.....	91
5.2.5 Plasmalogens in Ion Transport.....	92
5.2.6 Plasmalogens in High-Density Lipoprotein.....	93
5.2.7 Plasmalogens, Cholesterol Oxidation, Efflux and Atherosclerosis.....	93
5.2.8 Plasmalogens and Their Antioxidant Activity.....	94
5.2.9 Plasmalogens and Generation of Long-Chain Aldehydes....	97
5.2.10 Plasmalogens in Differentiation.....	97
5.2.11 Plasmalogens in the Ocular Development.....	98
5.2.12 Plasmalogens as Precursors for the Platelet- Activating Factor.....	98
5.3 Conclusion.....	99
References.....	99
6 Involvement of Plasmalogens in Neurological Disorders.....	107
6.1 Introduction.....	107
6.2 Plasmalogens in Neurological Disorders.....	108
6.2.1 Plasmalogens in Ischemic Injury.....	110
6.2.2 Plasmalogens in Alzheimer Disease.....	111
6.2.3 Plasmalogens in Spinal Cord Injury.....	114
6.2.4 Plasmalogens in Peroxisomal Disorders.....	115
6.2.5 Plasmalogens in Sjogren-Larsson Syndrome.....	118
6.2.6 Plasmalogens in Malnutrition.....	119
6.2.7 Plasmalogens in Fetal Alcohol Syndrome.....	119
6.2.8 Plasmalogens in Diabetic Heart.....	119
6.2.9 Plasmalogens in Other Neurological Disorders.....	120
6.3 Plasmalogens in Uremic Patients.....	120
6.4 Plasmalogens in Myelin-Deficient Mutant Mice.....	121
6.5 Conclusion.....	121
References.....	122
7 Synthesis of Platelet-Activating Factor in Brain.....	129
7.1 Introduction.....	129
7.2 Biosynthesis of PAF.....	130
7.2.1 Remodeling Pathway (Deacylation/Reacylation Pathway)....	130

7.2.2	Cytosolic Phospholipase A ₂ (cPLA ₂)	131
7.2.3	Acetyl-CoA/Lyso-PAF Acetyltransferase.....	133
7.2.4	CoA-Independent Transacetylase.....	135
7.3	De Novo Synthesis of PAF	137
7.3.1	1-Alkyl-2-lyso- <i>sn</i> -glycero-3-phosphate (Alkyllyso- GP)/Acetyl-CoA Acetyltransferase.....	138
7.3.2	1-Alkyl-2-acetyl- <i>sn</i> -glycero-3-phosphate Phosphohydrolase.....	140
7.3.3	1-Alkyl-2-acetyl- <i>sn</i> -glycerol/CDP-choline Phosphotransferase	140
7.4	Oxidative Fragmentation Pathway for PAF Synthesis.....	142
7.5	Regulation of PAF Synthesis	143
7.6	Conclusion.....	145
	References.....	146
8	Degradation of Platelet-Activating Factor in Brain	151
8.1	Introduction	151
8.2	PAF-Acetyl Hydrolases in Brain and Plasma	152
8.3	Purification and Properties of PAF-Acetyl Hydrolases	153
8.3.1	Types I PAF-Acetyl Hydrolases in Mammalian Tissues	154
8.3.2	Types II PAF-Acetyl Hydrolases in Mammalian Tissues	155
8.3.3	PAF-Acetyl Hydrolases in Mammalian Plasma	156
8.4	Other PAF-Acetyl Hydrolases	158
8.5	Regulation and Roles of PAF-Acetyl Hydrolases in Brain.....	159
8.6	PAF Hydrolyzing Phospholipase C	164
8.7	Other PAF Hydrolyzing Lipases	165
8.8	Conclusion.....	166
	References.....	166
9	Roles of Platelet-Activating Factor in Brain	171
9.1	Introduction	171
9.2	PAF Receptors in Brain	174
9.3	Translocation of PAF from Synthetic Site to Cell Surface Receptors.....	175
9.4	PAF-Receptor-Mediated Signal Transduction.....	176
9.5	Roles of PAF in brain.....	179
9.5.1	PAF in Gene Expression	179
9.5.2	PAF in Neural Cell Migration.....	182
9.5.3	PAF in Long-Term Potentiation.....	183
9.5.4	PAF in Glutamate-Mediated Neurotoxicity	184
9.5.5	PAF and Calcium Influx	186
9.5.6	PAF in Neuroinflammation	186

9.5.7	PAF in Cerebral Blood Flow and Blood–Brain Barrier Permeability	187
9.5.8	PAF in Apoptosis	188
9.5.9	PAF in Noniception	189
9.5.10	PAF in Immune Response	190
9.6	Conclusion.....	190
	References.....	191
10	Involvement of Platelet-Activating Factor in Neurological Disorders.....	197
10.1	Introduction.....	197
10.2	Involvement of Platelet-Activating Factor in Neurological Disorders	198
10.2.1	PAF in Ischemia.....	199
10.2.2	PAF in Head Injury and Spinal Cord Trauma.....	200
10.2.3	PAF in Meningitis.....	201
10.2.4	PAF in HIV Infection	202
10.2.5	PAF in Prion Diseases	203
10.2.6	PAF in Multiple Sclerosis.....	204
10.2.7	PAF in Miller-Dieker Lissencephaly.....	204
10.2.8	PAF in Migraine Attacks	205
10.2.9	PAF in Kainic-Acid-Mediated Neurodegeneration	205
10.3	Involvement of PAF in Nonneural Injuries.....	206
10.4	Consequences of Altered PAF Acetyl Hydrolase in Cardiovascular System.....	207
10.5	Molecular Mechanism of PAF-Mediated Neural Injury.....	208
10.6	Clinical Application of PAF Antagonists for the Treatment of Neurological Disorders	210
10.7	Conclusion.....	211
	References.....	211
11	Biochemical Effects of Nonphysiological Antitumor Ether Lipids.....	219
11.1	Introduction.....	219
11.2	Effect of AEL on Enzymes Involved in Signal Transduction.....	222
11.2.1	Effects of AEL on Phospholipases A ₂ , C, and D	223
11.2.2	Effects of AEL on Protein and Lipid Kinases	224
11.2.3	Effect of AEL on Cellular Receptors	228
11.2.4	Other Effects of AEL on Cellular Metabolism.....	230
11.3	Molecular Mechanism and Site of Action of AEL	231
11.4	Conclusion.....	232
	References.....	232

12 Perspective and Directions for Future Developments on Ether Lipids.....	237
12.1 Introduction.....	237
12.2 Interactions Among Glycerophospholipid, Sphingolipid, and Cholesterol-Derived Lipid Mediators	239
12.3 Interactions Between Ether Lipid and Sphingolipid-Derived Lipid Mediators.....	240
12.4 Interactions Between Sphingolipid and Cholesterol-Derived Lipid Mediators.....	243
12.5 Use of Lipidomics, Proteomics, and Genomics for Characterization of Enzymes, Lipid Mediators, and Signal Transduction Process in Normal and Diseased Brain Tissues.....	244
12.6 Use of RNAi for the Treatment of Ether Lipid-Related Neurodegenerative Diseases	246
12.7 Conclusion.....	248
References.....	248
Index.....	253